Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02454478
Recruitment Status : Completed
First Posted : May 27, 2015
Results First Posted : February 8, 2019
Last Update Posted : March 19, 2019
Sponsor:
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

Brief Summary:
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.

Condition or disease Intervention/treatment Phase
Carcinoma, Renal Cell Drug: Lenvatinib Drug: Everolimus Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic RCC
Actual Study Start Date : July 1, 2015
Actual Primary Completion Date : May 29, 2017
Actual Study Completion Date : May 29, 2017


Arm Intervention/treatment
Experimental: Lenvatinib plus Everolimus Drug: Lenvatinib
Drug: Everolimus
Other Name: Lenvatinib plus Everolimus orally once a day




Primary Outcome Measures :
  1. Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT) [ Time Frame: From first dose of study drug up to Cycle 1 Day 28 (Cycle length=28 days) ]
    DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 30 days after the last dose of study drug (up to approximately 21.5 months) ]

Secondary Outcome Measures :
  1. Cmax: Maximum Observed Plasma Concentration for Levatinib and Everolimus [ Time Frame: Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days) ]
  2. Css,Max: Maximum Observed Plasma Concentration at Steady State for Levatinib and Everolimus [ Time Frame: Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days) ]
  3. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Levatinib and Everolimus [ Time Frame: Cycle 1 Day 1 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days) ]
  4. Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for Levatinib and Everolimus [ Time Frame: Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days) ]
  5. AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Levatinib and Everolimus [ Time Frame: Cycle 1 Day 1 and Cycle 1 Day 15 predose and at 1, 2, 4 ,8, and 24 hours postdose (Cycle length=28 days) ]
  6. Number of Participants With Best Overall Response (BOR) [ Time Frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months) ]
    BOR included complete response (CR), partial response (PR), stable disease (SD), and PD (progressive disease). BOR was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1

  7. Objective Response Rate (ORR) [ Time Frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months) ]
    ORR was defined as the percentage of participants who achieved BOR of CR or PR. ORR was assessed using RECIST 1.1.

  8. Disease Control Rate (DCR) [ Time Frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 23 months) ]
    DCR was defined as the percentage of participants who achieved BOR of CR, PR, or SD. DCR was assessed based on RECIST 1.1.

  9. Number of Participants With the Minimum Percent Change From Baseline in the Sum of Diameters of Target Lesions [ Time Frame: Baseline up to first tumor assessment at which diameter of target lesions were available (up to approximately 23 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Voluntary agreement to provide written informed consent of this study.
  2. Willing and able to comply with all aspects of the protocol after being fully informed of the content.
  3. Males or females aged greater than or equal to 20 years at the time of informed consent.
  4. Histological or cytological confirmation of RCC.
  5. Participants must have confirmed diagnosis of unresectable advanced and/or metastatic RCC.
  6. Disease progression following vascular endothelial growth factor (VEGF) targeted therapy.
  7. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1.
  8. Adequately controlled blood pressure with or without the use of antihypertensive agents.
  9. Participants with adequate function of major organs.
  10. Adequate blood coagulation function, defined as international normalized ratio (INR) less than or equal to 1.5.
  11. Survival expectation of 3 months or longer after study enrollment.
  12. Participants with adequate washout period from the end of prior treatment to the start of study drug administration.
  13. Females of childbearing potential must not have had unprotected sexual intercourse within 28 days before participant registration and must agree to use a highly effective method of contraception throughout the entire study period and for 30 days after final administration of investigational drug. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during this study period or for 30 days after investigational drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before administration and must continue to use the same contraceptive during this study and for 30 days after investigational drug discontinuation.
  14. Male participants and their female partners must meet the criteria above.

Exclusion Criteria:

  1. Participants with central nervous system (CNS) metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example, radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
  2. Prior exposure to lenvatinib.
  3. Participants who have not recovered from toxicities to less than or equal to Grade 1 as a result of prior anticancer therapy, except alopecia.
  4. Major surgery within 3 weeks prior to the first dose of lenvatinib.
  5. Participants with a urine protein greater than or equal to 1 gram per 24 hours (g/24 hours).
  6. Uncontrollable diabetes as defined by fasting glucose greater than 1.5* upper limit of normal (ULN).
  7. Fasting total cholesterol greater than 7.75 millimole per liter (mmol/L) (greater than 300 milligram per decilitre [mg/dL]).
  8. Fasting triglycerides greater than 2.5 * ULN.
  9. Any condition that might affect the absorption of lenvatinib and/or everolimus.
  10. Significant cardiovascular impairment.
  11. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring.
  12. Active hemoptysis.
  13. Active infections that require systemic treatment.
  14. Human immunodeficiency virus (HIV) positive.
  15. Hepatitis B virus (HBV).
  16. A history of interstitial pneumonia with clinical manifestation or as confirmed by means of diagnostic imaging.
  17. Medical need for the continued use of potent or moderate inhibitors of cytochrome P450 3A (CYP3A) or P-gp, or potent or moderate inducer of CYP3A.
  18. Known intolerance to lenvatinib (or any of the excipients) or known hypersensitivity to everolimus (or any of the excipients) or rapmycins (sirolimus, temsirolimus and so on).
  19. Alcohol or drug dependency or abuse, inability to comply with every aspects of the study protocol, or any physical or mental conditions that in the opinion of the investigators would preclude the participant's participation in the study.
  20. Females who are pregnant or breastfeeding (not eligible even she discontinues breastfeeding).
  21. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02454478


Locations
Layout table for location information
Japan
Eisai Trial Site #1
Chiba, Japan
Eisai Trial Site #1
Tokyo, Japan
Eisai Trial Site #2
Tokyo, Japan
Sponsors and Collaborators
Eisai Co., Ltd.
  Study Documents (Full-Text)

Documents provided by Eisai Inc. ( Eisai Co., Ltd. ):
Study Protocol  [PDF] March 25, 2015
Statistical Analysis Plan  [PDF] February 8, 2016


Layout table for additonal information
Responsible Party: Eisai Co., Ltd.
ClinicalTrials.gov Identifier: NCT02454478    
Other Study ID Numbers: E7080-J081-112
First Posted: May 27, 2015    Key Record Dates
Results First Posted: February 8, 2019
Last Update Posted: March 19, 2019
Last Verified: September 2018
Keywords provided by Eisai Inc. ( Eisai Co., Ltd. ):
lenvatinib
Everolimus
Carcinoma
Unresectable advanced renal cell carcinoma
Metastatic renal cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Sirolimus
Everolimus
Lenvatinib
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action